XML 35 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenues:    
License fee and milestone revenue $ 14,259 $ 24,838
License fee and milestone revenue from affiliated entity 106,250 106,250
Grants and miscellaneous revenue 1,334,716 1,562,033
Total revenues 1,455,225 1,693,121
Operating expenses:    
Research and development 5,115,112 4,042,579
General and administrative 2,974,153 2,488,088
Gain on sale of assets 0 (651,000)
Total operating expenses 8,089,265 5,879,667
Loss from operations (6,634,040) (4,186,546)
Other income (expense):    
Interest and other income, net 39,460 31,544
Change in fair value of common stock warrants (1,427,616) (3,548,173)
Loss on investment in affiliated entity (836,084) (561,544)
Net loss (8,858,280) (8,264,719)
Net loss attributable to non-controlling interest 14,160 9,770
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (8,844,120) $ (8,254,949)
Loss per common share—basic and diluted:    
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders (in USD per share) $ (0.06) $ (0.06)
Weighted average number of common shares outstanding—basic and diluted 156,155,532 134,968,394